Four-Year Follow-Up after High-Dose Immunosuppressive Therapy (HDIT) for Severe Systemic Sclerosis (SSc).
Richard A. Nash(Colorado Blood Cancer Institute), Daniel E. Furst(University of California, Los Angeles), Maureen D. Mayes(The University of Texas Health Science Center), Keith M. Sullivan(Duke Medical Center), Gretchen Henstorf(Fred Hutch Cancer Center), Mark H. Wener(University of Washington), James R. Seibold(University of Michigan), Leslie J. Crofford(Vanderbilt University Medical Center), Leona Holmberg(University of Washington), B McLaughlin(Fred Hutch Cancer Center), Peter A. McSweeney(Mesoblast (United States)), Howard M. Shulman(Fred Hutch Cancer Center), Jerry A. Molitor(Virginia Mason Medical Center), Ted Gooley(Fred Hutch Cancer Center), Kevin T. McDonagh(University of Michigan), J. Lee Nelson(University of Washington)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k